Key facts
- Senseera’s last known valuation is $15.6M (Jan 2025).
- It has raised $8.4M; the latest was Seed Round ($7.1M) in Jan 2025.
- Notable investors include Lightspeed Venture Partners, DayOne Accelerator, I-Next Capital, Next Capital Partners, RISE (Accelerator) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Senseera
- ·The full record, as it builds
Funding rounds
No funding rounds for Senseera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Senseera
Developer of liquid biopsy blood tests designed for early detection and monitoring of cancer and other diseases. The company offers chromatin-based diagnostics combining molecular biology, sequencing, and advanced computational analysis to extract epigenetic signals from circulating blood fragments, enabling patients and clinicians to access accurate, tissue-agnostic, and affordable clinical insights for disease screening, monitoring, and precision medicine.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2020
- Employees
- 19
- Website
- senseerahealth.com/
- Ownership
- Privately Held (backing)
Senseera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Senseera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Senseera in its N-PORT filings yet. We sweep new filings monthly.